Investing Profile

Vasudev Bailey

VC
General Partner at ARTIS Ventures
av.co/vasudev-baileySan Francisco, California
Photo of Vasudev Bailey, General Partner at Artis Ventures (AV)

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
Artis Ventures (AV) General Partner
$250K - $25.0M
$10.0M
19
CompanyStageDateRound SizeTotal Raised
Unnatural Products
Series BMar 2026$45M
Series ADec 2023$32M
SeedSep 2019$6M
$83M
Co-investors: Ameena El-Bibany (Artis Ventures (AV)), Nicholas Shekerdemian (The Venture Collective (TVC))
Eko Health
Series DJun 2024$41M
Series CNov 2020$65M
Series BSep 2019$20M
Series AMar 2018$5M
$140M
Co-investors: Pieter Kemps (Peak XV Partners (formerly Sequoia Capital India & SEA)), Rob Toews (Radical Ventures), Corey Mulloy (Highland Capital Partners), Ryan Drant (Questa Capital), Stephen Hays (What If Ventures), Jeremy Fiance (The House Fund), Charles Seely (QuantrolOx), Michael Baum
OverT Bio
SeedMay 2024$16M
$16M
Co-investors: Sara Choi (Wing Venture Capital)
Freenome
Series FFeb 2024$250M
Series DDec 2021$300M
Series BJul 2019$160M
$1.1B
Co-investors: Vijay Pande (Andreessen Horowitz), Amir Nashat (Polaris Venture Partners), Peter Kolchinsky (RA Capital), Jeffrey Schwartz (Bain Capital Life Sciences), Skip Fleshman (Asset Management Ventures), Daniel Coley (Cofounders Capital), Anne Wojcicki (23andMe)
Ozlo Sleep
Series AAug 2023$10M
$10M
ONI
Series BDec 2021$75M
$75M
Co-investors: Keith Crandell (ARCH Venture Partners), David Schwab (Vertical Venture Partners), Mike Pellini (Section 32), Paul Conley (Paladin Capital Group)
Delix Therapeutics
Series ASep 2021$70M
$70M
Co-investors: Andrew Levin (RA Capital), Ken Belotsky (Negev Capital), Matias Serebrinsky (PsyMed Ventures)
Excision BioTherapeutics
Series AFeb 2021$60M
SeedSep 2017$10M
$81M
Co-investors: Brian Keil (Alumni Ventures ), Lawrence Jen (Alumni Ventures ), Chris Sklarin (Alumni Ventures ), Anton Simunovic (Alumni Ventures ), Stuart Peterson (Artis Ventures (AV)), Ben Kong (Rebel Fund), Andre De Baubigny (Modern Venture Partners), Daniel Rothman